ヨーロッパのてんかん(Epilepsy)治療薬市場...市場調査レポートについてご紹介

【英文タイトル】Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Epilepsy: An overview
About the disease
Types of epilepsy
Signs and symptoms
Diagnosis
Epidemiology
Economic burden

PART 06: Pipeline portfolio
Key information of few pipeline candidates

PART 07: Market landscape
Market overview
Epilepsy drugs market in Germany
Epilepsy drugs market in the UK
Five forces analysis

PART 08: Market segmentation by generation of drugs
Segmentation of epilepsy drugs market in Europe by generation of drugs

PART 09: Market drivers
Unmet medical needs
Rise in patient population
Promising drug pipeline

PART 10: Impact of drivers

PART 11: Market challenges
Expiry of patents
Stringent regulatory guidelines
Social stigma associated with epilepsy

PART 12: Impact of drivers and challenges

PART 13: Market trends
Reformulation of marketed drugs
Emergence of new-generation anti-epileptic drugs

PART 14: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 15: Key vendor analysis
Eisai
GlaxoSmithKline
Pfizer
UCB

PART 16: Appendix
List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Cost per person in Europe 2010
Exhibit 03: Pipeline portfolio
Exhibit 04: Epilepsy drugs market in Europe 2014-2019 ($ millions)
Exhibit 05: Epilepsy drugs market in Europe 2014
Exhibit 06: Epilepsy drugs market in Germany 2014-2019 ($ millions)
Exhibit 07: Epilepsy drugs market in the UK 2014-2019 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of epilepsy drugs market in Europe by generation of drugs
Exhibit 10: Impact of drivers
Exhibit 11: Impact of drivers and challenges
Exhibit 12: Eisai: Key takeaways
Exhibit 13: Eisai: Fycompa product profile
Exhibit 14: Eisai: Revenue of Fycompa in EMEA 2013 and 2014 ($ millions)
Exhibit 15: Eisai: Inovelon product profile
Exhibit 16: Eisai: Revenue of Inovelon in EMEA 2013 and 2014 ($ millions)
Exhibit 17: Eisai: Zebinix product profile
Exhibit 18: Eisai: Revenue of Zebinix in EMEA 2013 and 2014 ($ millions)
Exhibit 19: Eisai: Zonegran product profile
Exhibit 20: Eisai: Revenue of Zonegran 2013 and 2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Key takeaways
Exhibit 22: GlaxoSmithKline: Lamictal product profile
Exhibit 23: GlaxoSmithKline: Revenue of Lamictal in Europe 2011-2014 ($ millions)
Exhibit 24: GlaxoSmithKline: Trobalt product profile
Exhibit 25: Pfizer: Key takeaways
Exhibit 26: Pfizer: Lyrica product profile
Exhibit 27: Pfizer: Revenue of Lyrica 2011-2014 ($ millions)
Exhibit 28: Pfizer: Neurontin product profile
Exhibit 29: Pfizer: Revenue of Neurontin 2011-2013 ($ millions)
Exhibit 30: UCB: Key takeaways
Exhibit 31: UCB: Keppra product profile
Exhibit 32: UCB: Revenue of Keppra in Europe 2011-2014 ($ millions)
Exhibit 33: UCB: Vimpat product profile
Exhibit 34: UCB: Revenue of Vimpat in Europe 2011-2014 ($ millions)
Exhibit 35: UCB: Product segmentation by revenue 2014
Exhibit 36: UCB: Product segmentation by revenue 2013 and 2014
Exhibit 37: UCB: Geographical segmentation by revenue 2014
Exhibit 38: UCB: Geographical segmentation by revenue 2013 and 2014


【レポート販売概要】

■ タイトル:ヨーロッパのてんかん(Epilepsy)治療薬市場
■ 英文:Epilepsy Drugs Market in Europe - Market Analysis 2015-2019
■ 発行日:2015年9月30日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7242
■ 調査対象地域:欧州
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。